Bristol-Myers Squibb (BMY) Reports Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year overall survival (OS) data from CheckMate -017 and CheckMate -057, two pivotal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
